Controversies in heart failure diagnosis

Slides:



Advertisements
Similar presentations
© 2010, American Heart Association. All rights reserved. A Validated Risk Score for In-hospital Mortality in Patients with Heart Failure from the American.
Advertisements

Practicalities of Palliative Care
Atrial Fibrillation Cardiovascular ISCEE 26th October 2010.
Karam Paul MS, MD, MBA, FACC Community Heart and Vascular.
Evaluation and Management of Acute Decompensated Heart Failure
Screening and diagnosis of AF and stratifying stroke risk.
2007 ACC/AHA Peri-operative guidelines- Anesthesia’s recommendations
Ischaemic Heart Disease- Implications of Gender Dr Kaye Birks School of Rural Health Monash University Australia Gender Competency Training for Medical.
Cardiac Arrhythmia in Thalassaemia Limassol, 24 – 26 October 2012 Malcolm Walker University College and the Heart Hospitals, London Clinical Director Hatter.
The patient with shortness of breath. Differential diagnosis Asthma Asthma COPD COPD Pneumonia Pneumonia Heart failure Heart failure PE PE Other Other.
Detection and management of preclinical heart failure
SEPSIS KILLS program Adult Inpatients
Student’s Research Group at the Department of Internal Medicine, Hypertension and Angiology The Medical University in Warsaw PULMONARY EMBOLISM – TOUGH.
Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy.
Patients with suspected syncope should be investigated by cardiologists Dr NR Stout.
The role of biomarkers in the diagnosis of cardiac dysfunction and heart failure in the elderly: time for a paradigm shift? Dr. Bert Vaes.
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Heart rate reduction with ivabradine and health related quality of life in.
analysis from the SHIFT study
Dorset Improving Diagnosis of Heart Failure Implementation of BNP Measuring in General Practice Ist Project Steering Group 13 th Sept 2011.
Heart Failure Whistle Stop Talks No 1 HFrEF and HFpEF Definitions for Diagnosis Susie Bowell BA Hons, RGN Heart Failure Specialist Nurse.
ACUTE CORONARY SYNDORME EARLY RISK STRATIFICATION Sarah Jamison March 2003.
Cost-Conscious Care Presentation Follow-up Chest X-Ray in Patients Admitted for Community Acquired Pneumonia Huy Tran, PGY-2 12/12/2013.
May 23rd, 2012 Hot topics from the Heart Failure Congress in Belgrade.
Duchenne Muscular Dystrophy: Cardiac Management. Introduction Aim: early detection and treatment of deterioration in heart muscle function Cardiac disease.
CVD and co-morbidities What are the priorities? G.J. Geersing, General Practitioner MD PhD Julius Center UMC Utrecht EPCCS conference 2014 Groningen.
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.
VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Main results Swedberg K, et al. Lancet. 2010;376(9744):
To assess the prognostic value of variability in home-measured blood pressure (BP) and heart rate (HR) in a general population. Objective: Methods: BP.
Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure Systolic Heart.
Case 1 37-year old male comes to the hospital complaining of palpitation for 8 months, no other symptoms: no sweating, wt loss,ischaemic chest pain, anxiety.
Heart rate in heart failure: Heart rate in heart failure: risk marker or risk factor? A subanalysis of the SHIFT trial on behalf of the Investigators M.
Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure REMINDER* Gilles Montalescot, Bertram Pitt,
WELCOME BNP testing. Aims of this education package Better understanding of what BNP testing is How to appropriately use the test How to request the.
HF diagnosis: audit of NTproBNP uptake and outcomes across Sheffield An update on diagnosis and management of HF Dr Abdallah Al-Mohammad, MD, FRCP(Edin),
Ventilator-associated Pneumonia Among Elderly Medicare Beneficiaries in Long-term Care Hospitals William Buczko, Ph.D. Research Analyst Centers for Medicare.
Lothian Heart Failure Diagnostic Pathway
Chronic heart failure By Vishal Patel GPVTS1.
Lung Cancer Audit to patient Reference Group
Windhi Dwijanarko RSU DADI KELUARGA, PURWOKERTO
Hunter Syndrome: Why We Need to Diagnose and Treat Early
Prevalence of statin and beta-blocker use by clinical presentation
Expert Insights on Complex Clinical Cases of Edema
TACTICS-HF Trial design: Patients with acute heart failure (reduced or preserved ejection fraction) were randomized to tolvaptan 30 mg at 0, 24, and 48.
Lothian Heart Failure Diagnostic Pathway
Kaplan–Meier estimates of the incidence of first heart failure hospitalization during follow-up according to the statin category among patients with type.
Proportion of participants with type 2 diabetes (diabetes categories are defined according to the American Diabetes Association 2010 Diagnostic Guidelines),
Estimated HR as a function of absolute change in glycated hemoglobin (HbA1c; from index to measurement 22–26 months after). Estimated HR as a function.
Patients’ pathways to Accident and Emergency (A&E)
Connie W. Tsao et al. JCHF 2016;4:
Effects of Pay-for-Performance on the Quality of Primary Care in England Mean Scores for Clinical Quality at the Practice Level for Aspects of Care for.
Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.
Time to death from diabetes diagnosis for propensity-matched sample adjusted for age, gender, race, and other conditions. Time to death from diabetes diagnosis.
Estimated HR as a function of mean residual of glycated hemoglobin (HbA1c) measurements to the line connecting index HbA1c and HbA1c measurement 22–26 months.
Algorithm for the investigation of patients with elevated cardiac troponin concentrations in the context of an alternative acute illness. Algorithm for.
Enrollment of patients.
Associations between type of MI and incident HF
Revised taxonomy of integrated palliative care initiatives in Europe (changes are highlighted in green; CHF, chronic heart failure; COPD, chronic obstructive.
Increase of physical activity over time associated with lower HF risk
Algorithm for haemodynamic evaluation in the elderly.
Taxonomy applied on a specialised homecare palliative care initiative in Germany (blue arrows; CHF, chronic heart failure; COPD, chronic obstructive pulmonary.
Introduction to Evidence Based Medicine
Relationship between time from diagnosis of type 2 diabetes to renal biopsy and the proportion of biopsies with any diabetic nephropathy (DN) and any non-diabetic.
Distribution of NEWS in the community by service
Days without gluten challenge
Slide 1: Target population/question
Slide 1: Target population/question
Twice daily regimen N=45 MDI regimen N=28 P Value
Identification of thresholds for significant renal recovery in relation to patient and renal survival. Identification of thresholds for significant renal.
The Ottawa COPD (chronic obstructive pulmonary disease) Risk Scale (OCRS) is used in the emergency department (ED) to identify patients with acute COPD.
Presentation transcript:

Controversies in heart failure diagnosis Dr. Frans Rutten, Utrecht, The Netherlands

Background Disease of the elderly (1% of HF aged <65 years) (Early) diagnosis of slow onset HF is in primary care ‘always’ left sided; only <1% cor pulmonale Prevalence 1-1.5% (20-30 patients per practice) 30% with a GP’s HF label: No HF 30% of HF patients unknown * never detected * detected (much) later in time course

ESC 2008 definition of heart failure I. Symptoms typical of heart failure and (not always!) II. Signs typical of heart failure and III. Objective evidence of a structural or functional abnormality of the heart at rest 2005: Only symptoms obligatory Objective evidence of (left) ventricular dysfunction - decreased LVEF (LVEF <45%) : HFREF - LV filling and relaxation abnormalities, ‘normal’ LVEF : HFPEF

When should we think of HF? Any patient with * shortness of breath * exercise intolerance/fatigue * peripheral oedema Especially in: Elderly (oldest old, multimorbidity, ‘fragile’) Prior myocardial infarction, other CHD (HFREF) Diabetes type II (HFPEF) Longstanding hypertension (HFPEF) Atrial fibrillation, (suspected) valvular disease COPD (labeled as COPD and ‘really’ COPD). Every year! Renal dysfunction (eGFR<30-45 ml/min/1.73m²)

Diagnosing heart failure is not easy! COPD HF rest 30 causes of dyspnoea  65 years: multimorbidity

a complex clinical syndrome What is heart failure ? a complex clinical syndrome (left) ventricular dysfunction with origin in heart : HFREF (left) ventricular dysfunction in response to endothelial dysfunction (DM, etc) and pressure overload (HT): HFPEF reduced ability of the ventricle(s) to fill with or eject blood The heart is unable to provide sufficient cardiac output to satisfy the metabolic needs of the body. backward failure forward failure Fluid retention compensation exercise intolerance tachycardia fatigue apical beat

symptoms and signs of HF

ESC guidelines 2008 Dickstein et al. Eur J Heart Fail 2008;10:933-

primary care ED Chance of having new onset HF? Chance of having new onset HF? Possible cause? Possible cause?

primary care ED 79 years old 64 years old Hypertension, diabetes, COPD ‘no’ comorbidity 30 pack years smoking 30 pack years smoking slowly increase in dyspnoea, fatigue acute dyspnoea, orthopnoea, 166/92, 92 bpm 166/92, 92 bpm Displaced apex, no fluid overload raised JVP, crepitations,oedema

Symptoms breathlessness (with exercise) exercise intolerance always Fatigue ankle oedema (chronic venous insufficiency) not always! orthopnoea/paroxysmal nocturnal dyspnoea - early phase Increased urinating at night (>2x) - diuretic use weight gain (>2 kg/wk)

Signs crepitations raised JVP fluid overload oedema apical impulse displaced or sustained S3 gallop very rare heart murmur not very typical tachycardia, irregular pulse

Palpation of the apical impulse

Clinical models to detect or exclude HF in suspected patients from PC Male sex Orthopnoea Prior MI AUC 0.75 LVSD (LVEF <50%) JVP Age Prior MI, CABG, PCI Apical impulse AUC 0.82 (>700 patients) crepitations Murmur JVP Kelder et al. Submitted Prior MI AUC 0.66-0.79 (MICE, 6 of 9 studies) oedema Mant et al. HTA 2009;13:no 32 Fahey et al. Fam Pract 2007;24:628-

Clinical model (screening) elderly stable COPD Clinical models to detect or exclude HF in suspected patients from PC Age Male sex Prior MI, CABG, PCI Diabetes AUC 0.79 Orthopnoea Crepitations, elevated JVP, S3 gallop, ankle oedema Kelder et al Heart 2011 Apical impulse AUC 0.70 (screening elderly COPD patients) Heart rate >90 bpm BMI >30 kg/m² Rutten et al. BMJ 2005;331:1379 Clinical model (screening) elderly stable COPD

Essentials of clinical diagnostic models Signs or symptoms of fluid overload (diuretics, early phase) Displaced/broadened apical impulse murmur in elderly persons, male sex, prior CAD, diabetes Screening COPD: HR >90 bpm BMI >30 kg/m²

Additional tests slow onset acute onset test treatment with diuretics : NO test treatment with diuretics ? ECG: when normal HF <10% ECG: when normal HF <2% Chest X-ray ? Chest X-ray ? NTproBNP: when normal HF <10% NTproBNP: when normal HF <2% Echocardiogram valvular disease LVH, CMP causes of HF wall motion abnormalities other cardiac abnormalities

ESC guidelines 2008 5 key diagnostic 'tests' Dickstein et al. Eur J Heart Fail2008; 10:933-

Multivariable models for detection/exclusion (slow onset) HF Clinical model 0.75 + ECG 0.86 Clinical model 0.82 + ECG 0.83 + Chest X-ray 0.84 + ntproBNP 0.86 Kelder et al. Submitted Clinical model 0.66-0.79 (6 of 9 studies) + ECG 0.76-0.83 + ntproBNP 0.83-0.93 Mant et al. HTA 2009;13:no 32 Clinical model 0.79 + ECG 0.85 + ntproBNP 0.91-0.92 Kelder et al. Heart 2011;97:959 Fahey et al. Fam Pract 2007;24:628

Multivariable models for detection/exclusion (slow onset) HF Clinical model 0.70 (screening elderly COPD patients) + ECG 0.75 + Chest X-ray 0.73 + ntproBNP 0.77 Rutten et al. BMJ 2005;331:1379 Fahey et al. Fam Pract 2007;24:628-

Dutch adaptation of the ESC guidelines 2008 Suspected heart failure symptoms and signs Acute Slow onset ECG, (NT-pro)BNP, chest X-ray ECG, (NT-pro)BNP, chest X-ray ECG normal and NT-proBNP<400 pg/ml BNP<100 pg/ml ECG abnormal or NT-proBNP≥400 pg/ml BNP≥100 pg/ml ECG abnormal or NT-proBNP≥ 125 pg/ml BNP≥ 35 pg/ml ECG normal and NT-proBNP<125 pg/ml BNP< 35 pg/ml Heart failure very unlikely Echocardiography Heart failure very unlikely Hartfalen richtlijn. Hoes et al. 2010

Causes for elevated ntproBNP levels acute dyspnoea slow onset dyspnoea ACS age >75 years pulmonary embolism atrial fibrillation acute renal failure renal dysfunction pulmonary artery hypertension LVH sepsis severe COPD

Conclusions Dyspnoea, exercise intolerance/ fatigue, ankle oedema: Always think of HF Signs or symptoms of fluid overload (diuretics, early phase) Displaces/broadened apical impulse, murmur essentials in elderly persons, male sex, prior CAD, diabetes Additional tests: ntproBNP most valuable Lower exclusionary cut-points ntproBNP for slow onset than acute onset HF Echocardiogram for diagnosis AND cause(s) AND whether HFPEF/HFREF Always consider cause of HF, especially treatable ones (valves)!!